Scandion Oncology A/S Total Liabilities
Scandion Oncology A/S total liabilities. Based on the latest financial reports, Scandion Oncology A/S (SCOL) has total liabilities worth Skr10.01 Million SEK (≈ $1.08 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Scandion Oncology A/S defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Scandion Oncology A/S (2017–2024)
Total liabilities of Scandion Oncology A/S from 2017 to 2024. This chart illustrates how Scandion Oncology A/S's total liabilities have evolved over time, based on quarterly financial data.
Scandion Oncology A/S Competitors by Total Liabilities
The table below lists competitors of Scandion Oncology A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qlosr Group AB Series B
ST:QLOSR-B
|
Sweden | Skr6.50 Million |
|
Lion Group Holding Ltd
NASDAQ:LGHL
|
USA | $32.32 Million |
|
ECORUB AB B
F:7M8
|
Germany | €37.93 Million |
|
Kiliaro AB
ST:KILI
|
Sweden | Skr15.91 Million |
|
Greenroc Mining PLC
LSE:GROC
|
UK | GBX2.85 Million |
|
Frontier IP Group Plc
LSE:FIPP
|
UK | GBX12.40 Million |
|
Global Lights Acquisition Corp Unit
NASDAQ:GLACU
|
USA | $2.99 Million |
|
Headlam Group
LSE:HEAD
|
UK | GBX244.70 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Scandion Oncology A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Scandion Oncology A/S balance sheet assets.
Liquidity & Leverage Metrics
Scandion Oncology A/S Total Liabilities Ratios Explained
Scandion Oncology A/S total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scandion Oncology A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scandion Oncology A/S (2017–2024)
The table below shows the annual total liabilities of Scandion Oncology A/S from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr10.01 Million ≈ $1.08 Million |
+191.19% |
| 2023-12-31 | Skr3.44 Million ≈ $369.98K |
-81.98% |
| 2022-12-31 | Skr19.07 Million ≈ $2.05 Million |
+63.33% |
| 2021-12-31 | Skr11.68 Million ≈ $1.26 Million |
-61.77% |
| 2020-12-31 | Skr30.54 Million ≈ $3.29 Million |
+1852.47% |
| 2019-12-31 | Skr1.56 Million ≈ $168.35K |
+57.59% |
| 2018-12-31 | Skr992.64K ≈ $106.82K |
+95.01% |
| 2017-12-31 | Skr509.02K ≈ $54.78K |
-- |
About Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more